Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Generate Biomedicines, Inc.NASDAQ: GENB

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents of $160.58M in Q1 FY2026

Q1 FY2026 cash & equivalents was $160.58M.

Context

  • Cash & equivalents amounted to 25.7% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$160.58M— QoQ
Last fiscal yearDec 2025
$121.65M-31.0% YoY
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-31.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
121.65M USD
Year-over-year change
-31.0%
1-year CAGR
-31.0%

Cash & Equivalents vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's Mar 2026 cash & equivalents of $160.58M is the 3rd highest of the 5 companies compared; the peer median is $117.67M.
  • Cash & equivalents amounts to 25.7% of total assets for GENB, versus a peer median of 20.7%.
GENB Competitors Peer median
Cash & Equivalents for GENB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABCLAbCellera Biologics Inc.Sep 2026$163.8M +97.0%-30.7%10.9%
INBXInhibrx Biosciences, Inc.Mar 2026$161.66M -25.3%-23.2%87.9%
GENBGenerate Biomedicines, Inc.Mar 2026$160.58M ——25.7%
STROSutro Biopharma, Inc.Mar 2026$73.68M -30.6%+7.1%30.4%
ABSIAbsci CorporationMar 2026$8.63M -81.6%-30.6%4.4%
Peer median (excluding GENB) $117.67M-28.0%-26.9%20.7%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.